RPG Life Sciences (RPGLIFE) Q1 24/25 earnings summary

Executive summary

• Achieved strong all-round performance in Q1 FY25, with double-digit growth across all business segments and continued margin expansion.

• Transformation agenda focused on growth, digitalization, and operational excellence remains central to strategy.

• Unaudited financial results for the quarter ended June 30, 2024, were approved by the Board on July 19, 2024.

• The review by independent auditors found no material misstatements in the financial statements.

Financial highlights

• Q1 FY25 revenue from operations rose 12% year-over-year to ₹165.4 crore (₹16,542 lakhs), with total income at ₹16,779 lakhs.

• EBITDA increased 21% to ₹41.4 crore, with margin improving to 25.1% from 22.1% in Q1 FY24.

• PAT grew 21% to ₹26.8 crore (₹2,676 lakhs), with PAT margin at 16.2% versus 13.4% last year.

• EPS up 21% year-over-year, reaching ₹16.18 compared to ₹13.36 in Q1 FY24.

• Upward trajectory in revenue, EBITDA, and PAT maintained over multiple years.

Outlook and guidance

• Focus on scaling domestic and global businesses through new products, markets, and capacity expansion.

• Continued emphasis on cost control, process efficiencies, and strong governance.

• R&D pipeline in niche areas and M&A opportunities to drive future growth.